Raymond James: 'we continue to see a highly attractive long-term risk/reward skew for EWTX'
Tweet Send to a Friend
Raymond James analyst Martin Auster reiterated a Strong Buy rating and $46.00 price target on Edgewise Therapeutics (NASDAQ: EWTX).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
